Stocks making the biggest moves midday: Cerebras, Marvell, Intel, Corning & more

Midday trading was led by multiple tech and AI names, with Intel up 12%, Cerebras up 20%, Marvell up 13%, and Nvidia up nearly 2% on partnership and supply-chain news. Apple rose more than 2% into WWDC, while Corning gained about 6% after landing an Amazon data-center fiber deal and Nurix jumped nearly 7% on a Roche collaboration. Offsetting moves included Wix.com, which fell more than 5% after cutting its full-year bookings outlook to low-teens growth from mid-teens.

Analysis

This tape is less about broad AI enthusiasm than about where the AI capex stack is getting repriced. The clearest second-order signal is that infrastructure enablers are outperforming the headline AI leaders: memory, optics, packaging, and backup foundry capacity are all being bid because investors are extending the buildout timeline and assuming a more diversified supply chain. That matters because it shifts pricing power away from a few model vendors and toward a broader set of picks-and-shovels suppliers with more durable order visibility.

Intel’s move is especially interesting because the market is effectively assigning option value to a strategic manufacturing role rather than current earnings power. If even a small portion of external foundry demand materializes, the equity could re-rate on narrative before fundamentals catch up, but the reverse is also true: failure to win a meaningful tape-out within the next 1-2 quarters would likely give back most of today’s gain. Meanwhile, AMD, MU, AVGO, and NVDA benefit from the same read-through that AI demand is still outrunning supply, but Corning and Flex indicate the spend is broadening beyond chips into physical interconnect and systems integration.

The weaker side of the tape is guidance risk and ad-tech/software sensitivity. Wix’s cut is a reminder that subscale internet software still has limited pricing power in a slower SMB demand environment, and that growth deceleration can happen quickly when bookings are the leading indicator. For Apple, the market is paying for near-term AI optionality, but the true catalyst is not a keynote: it is evidence that AI features increase device replacement urgency over the next 6-12 months; if not, this will likely fade into a multiple-only rally.

The contrarian setup is that the best risk/reward may be in the underappreciated infrastructure names rather than the obvious AI beta leaders. Names tied to physical deployment and supply chain redundancy can compound for longer if AI spend remains resilient, while the most crowded beneficiaries could stall once the event-driven pop passes. In healthcare, Nurix remains a higher-quality catalyst trade because pharma partnership validation can extend for years if development milestones remain intact.

Key Decisions for Investors

• Overweight MRVL / FLEX / GLW basket for 1-3 month upside: these names are levered to AI infrastructure breadth, not just GPU cycles; risk/reward is better than chasing NVDA after a move, with lower headline multiple compression risk.
• Buy INTC call spreads or a small common starter position for 2-3 quarters: treat this as a strategic-option trade on foundry optionality; cut if there is no tangible customer confirmation within the next earnings cycle.
• Fade WIX on any relief bounce over the next 1-2 weeks: short into strength or buy put spreads; the booking guide cut implies multiple compression persists until management can stabilize demand, and small-cap software typically sees 15-25% downside on guidance resets.
• Long NRIX on a 3-6 month horizon via common or call spreads: partnership validation can re-rate the platform, and biopharma collaboration news tends to have a slower decay profile than hardware event trades.
• If chasing AI beta, prefer AVGO or MU over NVDA at current levels: both offer cleaner second-order exposure to memory/connectivity spend and may lag less if the market rotates from pure compute to broader buildout beneficiaries.